Although preclinical data supports its potent activity (Wang et al., 2019), real-world clinical evidence in advanced breast cancer, particularly combined with endocrine therapy in the HR+/HER2− gBRCA-mutated subtype, remains scarce. This evidence concerns the gene HR and breast cancer.